Your browser doesn't support javascript.
loading
The economic impact of delaying 5-alpha reductase inhibitor therapy in men receiving treatment for symptomatic benign prostatic hyperplasia.
Naslund, Michael; Eaddy, Michael T; Hogue, Susan L; Kruep, Eric J; Shah, Manan B.
  • Naslund M; Professor of Urology, University of Maryland School of Medicine, Baltimore.
  • Eaddy MT; Vice President, Data Analytics and Insights, Xcenda, Palm Harbor, FL.
  • Hogue SL; Employee of GlaxoSmithKline, Research Triangle Park, NC, when this study was conducted.
  • Kruep EJ; Director, Managed Markets, Xcenda.
  • Shah MB; Director, Data Analytics, Xcenda.
Am Health Drug Benefits ; 4(3): 155-62, 2011 May.
Article en En | MEDLINE | ID: mdl-25126348
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Health_economic_evaluation Idioma: En Año: 2011 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Health_economic_evaluation Idioma: En Año: 2011 Tipo del documento: Article